Abstract |
It seems to be a generally held view that there is no way of treating senile cataract successfully. However, this view is contradicted by the results of a long-term study carried out on 192 eyes treated with Conjunctisan A. According to these results lens opacities in senile cataract can indeed be influenced by therapy. Conjunctisan is a new therapeutic principle which exploits the effect of watersoluble protoplasmic elements, in particular proteins, ribonucleic and deoxyribonucleic acids, phospholipids, polysaccharides, lens-cell-specific nucleic acids and amino acid precursors from the lens, vitreous body, retina, optic nerve, cornea, conjunctiva and placenta. Over a period of observation of 5 years (1973-1978) Conjunctisan A eye drops were administered to the conjunctival sac twice or three times a day. Out of 192 eyes thus treated, lens opacification was halted in 36% and vision improved in 45%. These results concur with those of our earlier investigations on 74 eyes (1969-1973). It is also worth mentioning that opacification is slowed down much more than previously assumed on the basis of experience: this was demonstrated in a comparison with 75 cases of senile cataract that were not treated or treated only by conventional methods.
|
Authors | J Fuchs |
Journal | Klinische Monatsblatter fur Augenheilkunde
(Klin Monbl Augenheilkd)
Vol. 175
Issue 6
Pg. 799-805
(Dec 1979)
ISSN: 0023-2165 [Print] Germany |
Vernacular Title | Die konservative Behandlung des Altersstars mit Conjunctisan A Augentropfen. |
PMID | 552005
(Publication Type: English Abstract, Journal Article)
|
Chemical References |
- Drug Combinations
- Eye Proteins
- Ophthalmic Solutions
- Proteins
- Tissue Extracts
- conjunctisan A
|
Topics |
- Aged
- Cataract
(drug therapy, physiopathology)
- Drug Combinations
(therapeutic use)
- Eye Proteins
- Humans
- Lens, Crystalline
(metabolism)
- Ophthalmic Solutions
- Proteins
(therapeutic use)
- Tissue Extracts
(therapeutic use)
|